Fate Therapeutics develops induced pluripotent stem cell (iPSC)-derived, off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. The company's key competitive advantage lies in manufacturing scalable, universal cell products designed to overcome limitations of traditional cell therapies, with a focus on reducing the need for intensive conditioning regimens.
Cyborg Score Rationale
The company reduced operating expenses ~30% in 2025 versus 2024, demonstrating operational discipline. However, 2024 revenue declined 78.55% to $13.63 million with losses of $186.26 million. Despite strong clinical progress, the company faces typical early-stage biotech challenges with minimal revenue and significant R&D burn.
Top Insights
FT819 achieved outpatient dosing across autoimmune indications (15 SLE, 4 SSc, 1 IIM treated) and showed 3-month improvement in a systemic sclerosis patient
Company ended 2025 with $205.1 million in cash and projects runway through year-end 2027
Company plans to discuss a registrational trial for FT819 in 2026 under RMAT (Regenerative Medicine Advanced Therapy) designation
According to 7 analysts, average rating is "Buy" with 12-month price target of $3.92, representing 240.87% upside from recent levels
Named Competitors
CAR-T Cell Therapies — Autologous CAR-T for hematologic malignancies
Allogeneic Cell Therapies — Off-the-shelf CAR-T derived from iPSC/NK cells
Gene Editing Therapeutics — Base editing for cell and in vivo therapies
iPSC-derived Immunotherapies — CRISPR-based cell engineering for cancer
Recent Developments
(February 2026) Q4 2025 results reported with $205.1M cash, $1.4M Q4 revenue, and expanded FT819 clinical data showing efficacy and safety across autoimmune indications
(December 2025) Presented Phase 1 FT819 data at ASH 2025 showing progressive SLEDAI-2K score reductions with durable B-cell depletion
(November 2025) Received UK and EU regulatory authorization to activate ex-US clinical trial sites for FT819 enrollment
Open the full interactive Fate Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.